ATRC - AtriCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
38.65
+0.40 (+1.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close38.25
Open38.44
Bid0.00 x 1400
Ask0.00 x 3100
Day's Range37.66 - 38.87
52 Week Range22.57 - 38.88
Volume347,964
Avg. Volume223,208
Market Cap1.529B
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has received approval from the Food and Drug Administration (FDA) for the continuation of the trial under a Continued Access Protocol (CAP) with an additional patient enrollment of up to 85 patients and the opportunity to further expand to 250 patients while the pre-market application is under review.

  • Business Wire

    AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare Conference in San Francisco.

  • Business Wire

    AtriCure Names Two Industry Veterans to Board of Directors

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (HSIC) and a member of the Executive Committee.

  • Business Wire

    AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference

    AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City.

  • Business Wire

    AtriCure Reports Third Quarter 2019 Financial Results

    MASON, Ohio-- -- Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced third quarter 2019 financial results. ...

  • Business Wire

    AtriCure to Participate in Upcoming Investor Conferences

    AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in upcoming investor conferences.

  • Business Wire

    AtriCure to Announce Third Quarter 2019 Financial Results

    AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.

  • ACCESSWIRE

    AtriCure, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July, 30 2019 / AtriCure, Inc. (NASDAQ: ATRC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30:00 PM Eastern ...

  • Business Wire

    AtriCure Reports First Quarter 2019 Financial Results

    MASON, Ohio-- -- Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced first quarter 2019 financial results. ...

  • Business Wire

    AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart

    AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium. The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation.

  • Business Wire

    AtriCure to Announce First Quarter 2019 Financial Results

    AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019.

  • Business Wire

    AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference

    AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that it will present at the Needham & Company’s 18th Annual Healthcare Conference in New York on Wednesday, April 10, 2019.

  • GlobeNewswire

    Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth

    NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results

    MASON, Ohio-- -- 2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and related conditions, today announced fourth quarter and full year 2018 financial ...

  • Business Wire

    AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States

    AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with a comprehensive overview of the treatment of Afib during cardiac surgery. Founded in 1964, STS is a not-for-profit organization representing more than 7,500 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lungs, and esophagus, as well as other procedures within the chest.

  • Business Wire

    AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe

    cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block

  • Business Wire

    AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial

    AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™ trial (NCT03732794). Following Investigational Device Exemption (IDE) approval by the FDA, the first patient was treated by Dr. Niv Ad, at Washington Adventist Hospital in Takoma Park, Maryland.